## SINO BIOPHARMACEUTICAL LTD.

ISIN: KYG8167W1380 WKN: - Asset Class: Stock

biopharm.com



## **Company Profile**

Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.

Financial figures, Fiscal year: from 01.01. to 31.12.								
The second of the second	2023		2022		2021			
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity		
Current assets	26,210,016,000		29,118,149,000		28,750,629,000			
Common stock capital		456,493,000		465,823,000		508,193,000		
Fixed assets	43,819,228,000		42,809,369,000		45,309,953,000			
Equity capital of a company		42,025,321,000		42,600,730,000		46,152,617,000		
Cash and cash equivalents	8,039,406,000		9,717,093,000		11,742,783,000			
Accrued liabilities		0		0		0		
Other assets	-		-		-			
Current liabilities		24,890,179,000		22,623,966,000		18,771,034,000		
Prepayments and accrued income	-		-		-			
Non-current liabilities		2,510,092,000		5,861,811,000		8,311,900,000		
Different income		-		-		-		
Other liabilities		138,132,000		147,164,000		465,795,000		
Total assets	70,029,244,000	70,029,244,000	71,927,518,000	71,927,518,000	74,060,583,000	74,060,583,000		

Non-current liabilities		2,510,092,000		5,861,811,000		8,311,900,000
Different income		-		-		-
Other liabilities		138,132,000		147,164,000		465,795,000
Total assets	70,029,244,000	70,029,244,000	71,927,518,000	71,927,518,000	74,060,583,000	74,060,583,000
Balance notes						
				2023	2022	2021
Accounting standard				IFRS	IFRS	IFRS
Employees				25,806	26,272	25,579
Equity ratio				72.11%	72.02%	74.60%
Debt-equity ratio				38.68%	38.85%	34.04%
Others						
				2023	2022	2021
Tax Expense Rate				13.43%	13.08%	39.62%

## SINO BIOPHARMACEUTICAL LTD.

ISIN: KYG8167W1380 WKN: - Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	28,950,294,000	33,468,113,000	32,373,600,000
Net income	2,089,926,000	2,957,862,000	17,606,218,000
EBIT	827,286,522	860,165,560	735,304,403
Operating income before taxes	6,558,843,000	6,897,705,000	5,956,011,000
Cash Flow	-	8,511,885,000	11,635,230,000
Net interest income	-340,960,000	-276,319,000	-176,635,000
Research and development expenses	4,865,276,000	4,945,900,000	4,431,872,000
Income taxes	880,978,000	902,377,000	2,359,658,000
Result from investments in subsidaries, associates and other	-580,908,000	-177,892,000	16,427,977,000
Revenues per employee	134,509	152,742	151,749

<b>Board of Directors</b>	
Theresa Tse	Chairman of Supervisory Board
Kwok Tung Li	Member of Supervisory Board
Zheng Fei Lu	Member of Supervisory Board
Cheung Ling Cheng	Member of Supervisory Board
Da Kui Li	Member of Supervisory Board
Hong Lu	Member of Supervisory Board
Hsin Tse	Member of Supervisory Board
Lu Fu Zhang	Member of Supervisory Board
Ming Qin Li	Member of Supervisory Board
Ping Tse	Member of Supervisory Board
Zhou Shan Tian	Member of Supervisory Board

Members of Management Board				
Li Yi	Chairman of Managing Board			
Cheng Cheung Ling	Member of Executive Committee			
Li Mingqin	Member of Executive Committee			
Theresa Tse	Member of Executive Committee			
Tian Zhoushan	Member of Executive Committee			
Tse Hsin	Member of Executive Committee			
Tse Ping	Member of Executive Committee			
Tse, Eric	Member of Executive Committee			
Wang Shanchun	Member of Executive Committee			